These findings suggest that heterozygous loss of SPTBN1, SMAD3, and SMAD4 may synergistically promote colorectal carcinogenesis and contribute to poor prognoses in CRC patients. This evidence concerns the gene SPTBN1 and colorectal carcinoma.